Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Up 165.9% in March

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 114,600 shares, a growth of 165.9% from the February 28th total of 43,100 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 331,200 shares, the short-interest ratio is currently 0.3 days.

Chugai Pharmaceutical Stock Down 0.5 %

Shares of CHGCY stock traded down $0.12 during mid-day trading on Friday, hitting $23.09. 69,510 shares of the company’s stock were exchanged, compared to its average volume of 196,065. The stock has a market cap of $75.99 billion, a price-to-earnings ratio of 29.99 and a beta of 0.77. Chugai Pharmaceutical has a fifty-two week low of $14.52 and a fifty-two week high of $27.19. The stock has a 50-day simple moving average of $23.16 and a two-hundred day simple moving average of $22.90.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.18 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. As a group, analysts anticipate that Chugai Pharmaceutical will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.